Zobrazeno 1 - 2
of 2
pro vyhledávání: '"AC Rabe"'
Autor:
Joyce A. O'Shaughnessy, V Raja, J-A Brown, Yu-Sen Wang, Frankie A. Holmes, CF Eisenbeis, CR Osborne, AC Rabe, SR Fanning, GJ Robbins, G. Monaghan, MA Neubauer, JD Challagalla, C Taboada, Sharon Wilks, Lina Asmar, Svetislava J. Vukelja
Publikováno v:
Cancer Research. 71:P5-19
Introduction: Ixabepilone adds to the antitumor effectiveness of capecitabine in both ER+ and triple negative (TN) breast cancer. Ixabepilone has antitumor activity in taxane-refractory patients, and novel combinations are needed in this poor prognos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17fcaddc339395a0c042a4b1fce35308
https://doi.org/10.1158/0008-5472.sabcs11-p5-19-09
https://doi.org/10.1158/0008-5472.sabcs11-p5-19-09
Autor:
GL Wright, Kristi McIntyre, Joanne L. Blum, Svetislava J. Vukelja, Yunfei Wang, JC Andersen, Joyce A. O'Shaughnessy, AC Rabe, L Krekow, Lina Asmar, Sharon Wilks
Publikováno v:
Cancer Research. 71:PD01-01
Introduction: Fulvestrant is an effective endocrine therapy in patients with ER+ metastatic breast cancer (MBC) that has become resistant to non-steroidal aromatase inhibitors (NSAI). Dasatinib is a potent, broad spectrum ATP-competitive inhibitor of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebc53ecebf22f7b1a10227a39efdf082
https://doi.org/10.1158/0008-5472.sabcs11-pd01-01
https://doi.org/10.1158/0008-5472.sabcs11-pd01-01